The Psychiatric Genomics Consortium (PGC) is the largest consortium in the history of psychiatry. This global effort is dedicated to rapid progress and open science, and in the past decade it has delivered an increasing flow of new knowledge about the fundamental basis of common psychiatric disorders. The PGC has recently commenced a program of research designed to deliver “actionable” findings—genomic results that 1) reveal fundamental biology, 2) inform clinical practice, and 3) deliver new therapeutic targets. The central idea of the PGC is to convert the family history risk factor into biologically, clinically, and therapeutically meaningful insights. The emerging findings suggest that we are entering a phase of accelerated genetic discovery for multiple psychiatric disorders. These findings are likely to elucidate the genetic portions of these truly complex traits, and this knowledge can then be mined for its relevance for improved therapeutics and its impact on psychiatric practice within a precision medicine framework.

[AJP at 175: Remembering Our Past As We Envision Our Future

November 1946: The Genetic Theory of Schizophrenia

Franz Kallmann’s influential twin study of schizophrenia in 691 twin pairs was the largest in the field for nearly four decades. (Am J Psychiatry 1946; 103:309–322)]

精神病学基因组学联盟 (PGC) 是精神病学史上最大的联盟。这项全球努力致力于快速进步和开放科学，在过去十年中，它提供了越来越多关于常见精神疾病基本原理的新知识。 PGC 最近启动了一项研究计划，旨在提供“可操作”的发现——基因组结果，1) 揭示基础生物学，2) 为临床实践提供信息，3) 提供新的治疗靶点。 PGC 的中心思想是将家族史危险因素转化为具有生物学、临床和治疗意义的见解。新的发现表明，我们正在进入加速多种精神疾病基因发现的阶段。这些发现可能会阐明这些真正复杂特征的遗传部分，然后可以挖掘这些知识，以了解其与改进治疗的相关性及其对精准医学框架内精神病学实践的影响。

[AJP 175：在展望未来时铭记我们的过去

1946 年 11 月：精神分裂症的遗传理论

Franz Kallmann 对 691 对双胞胎进行的精神分裂症双胞胎研究颇具影响力，是该领域近四十年来最大规模的研究。 （美国精神病学杂志1946 年；103：309–322 ）]